A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors

被引：0
|
作者：
Rodon, J.
Infante, J.
Burris, H.
Tabernero, J.
Ranson, M. R.
Rouyrre, N.
Duval, V.
Silva, A.
Hackl, W.
Baselga, J.
机构：
[1] Vail Hebron Univ Hosp, Barcelona, Spain
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[4] Novartis Pharma AG, Basel, Switzerland
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-15-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-07
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
    Meng, Wei
    Wang, Baocheng
    Mao, Weiwei
    Wang, Jiajia
    Zhao, Yang
    Li, Qifeng
    Zhang, Chenran
    Ma, Jie
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2019, 81 (01): : 93 - 102
  • [22] PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells
    Chen, Jiezhong
    Shao, Renfu
    Li, Feng
    Monteiro, Michael
    Liu, Jun-Ping
    Xu, Zhi Ping
    Gu, Wenyi
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42 (12): : 1317 - 1326
  • [23] Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer
    Liu, Xueke
    Xu, Wei
    Li, Lele
    Zhang, Zhenyong
    Lu, Mei
    Xia, Xiaoping
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2024, 21 (10): : 1814 - 1823
  • [24] Drug irradiation schedule is decisive for radiosensitization by the novel dual PI3K and mTOR inhibitor NVP-BEZ235
    Kuger, S.
    Graus, D.
    Brendtke, R.
    Lutyj, P.
    Soukhoroukov, V
    Flentje, M.
    Djuzenova, C. S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 67 - 67
  • [25] The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
    Gan, Zhen Ying
    Fitter, Stephen
    Vandyke, Kate
    To, Luen B.
    Zannettino, Andrew C. W.
    Martin, Sally K.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (04) : 343 - 354
  • [26] A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
    Carlo, Maria I.
    Molina, Ana M.
    Lakhman, Yulia
    Patil, Sujata
    Woo, Kaitlin
    DeLuca, John
    Lee, Chung-Han
    Hsieh, James J.
    Feldman, Darren R.
    Motzer, Robert J.
    Voss, Amartin H.
    ONCOLOGIST, 2016, 21 (07): : 787 - 788
  • [27] Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
    Shunsuke Kondo
    Masaomi Tajimi
    Tomohiko Funai
    Koichi Inoue
    Hiroya Asou
    Vinay Kumar Ranka
    Volker Wacheck
    Toshihiko Doi
    Investigational New Drugs, 2020, 38 : 1836 - 1845
  • [28] Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC)
    Seront, Emmanuel
    Rottey, Sylvie
    Filleul, Bertrand
    Glorieux, Phillipe
    Goeminne, Jean Charles.
    Vandenbulcke, Jean-Marie
    Sautois, Brieuc
    Boegner, Petra
    Verschaeve, Vincent
    Gillain, Aline
    Van Maanen, Aline
    Machiels, Jean-Pascal H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Schram, Alison M.
    Gandhi, Leena
    Mita, Monica M.
    Damstrup, Lars
    Campana, Frank
    Hidalgo, Manuel
    Grande, Enrique
    Hyman, David M.
    Heist, Rebecca S.
    BRITISH JOURNAL OF CANCER, 2018, 119 (12) : 1471 - 1476
  • [30] A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Alison M. Schram
    Leena Gandhi
    Monica M. Mita
    Lars Damstrup
    Frank Campana
    Manuel Hidalgo
    Enrique Grande
    David M. Hyman
    Rebecca S. Heist
    British Journal of Cancer, 2018, 119 : 1471 - 1476
12345